
Beta Drugs Share Price Target 2027: Can It Reach Rs 2,230? Base Case at Rs 1,833
Beta Drugs share price Rs 1,764.20 (20 November 2026). Base target Rs 1,833, bull Rs 2,230, downside risk Rs 1,411. PE 36.78. 52W range Rs 990.10 to Rs 2,807.90.
Updated: 20 Nov 2026 • 11:11 am
Posted by:

Quick Answer
The Beta Drugs share price target for 2027 is Rs 1,833, about 3.9% above the current price of Rs 1,764.20. The bull case is Rs 2,230, and the downside risk level, which is not a target, is Rs 1,411. The base case assumes earnings per share grow 3.9% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 36.78. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing a Beta Drugs target price for 2027 should start with where the stock sits today. At Rs 1,764.20 on 20 November 2026, it is 37.2% below its 52-week high of Rs 2,807.90 and 78.2% above its 52-week low of Rs 990.10. That range spans 184% from low to high, so the entry point matters as much as the Beta Drugs price forecast itself.
This article builds the Beta Drugs share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.
Click Here – Get Free Investment Predictions
Beta Drugs Stock Analysis: Company Overview and Key Stats
Beta Drugs (NSE: BETA) has a market capitalisation of Rs 1,962 crore. In FY26 it reported revenue of Rs 396.01 crore and net profit of Rs 41.48 crore. The table collects the figures the Beta Drugs share price target is built on.
| Metric | Value |
|---|---|
| Company | Beta Drugs |
| NSE Ticker | BETA |
| CMP (20 November 2026) | Rs 1,764.20 |
| 52-Week High | Rs 2,807.90 |
| 52-Week Low | Rs 990.10 |
| Market Cap | Rs 1,962 crore |
| PE Ratio (TTM) | 36.78 |
| Industry PE | 40.13 |
| Price to Book | 4.48 |
| Return on Equity | 11.86% |
| Debt to Equity | 0.11 |
| EPS (TTM) | Rs 47.96 |
| Dividend Yield | 0.00% |
| 12-Month Base Target | Rs 1,833 |
| Bull Case | Rs 2,230 |
| Downside Risk Level (not a target) | Rs 1,411 |
Why Is Beta Drugs Share Price Target Set at Rs 1,833 for 2027?
The arithmetic is short. Trailing EPS of Rs 47.96 grown for one year gives a forward EPS estimate of Rs 49.83, and multiplying it by the unchanged PE of 36.78 gives the Rs 1,833 base-case Beta Drugs stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Beta Drugs Target Price: Five Years of Results
Beta Drugs grew revenue from Rs 184.59 crore in FY22 to Rs 396.01 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew more slowly, from Rs 24.83 crore to Rs 41.48 crore (13.7% a year), which points to margin pressure alongside the sales growth.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 184.59 | 24.83 | 25.82 | 0.00 |
| FY23 | 227.87 | 30.72 | 31.95 | 0.00 |
| FY24 | 297.07 | 36.44 | 37.90 | 0.00 |
| FY25 | 368.79 | 42.42 | 42.02 | 0.00 |
| FY26 | 396.01 | 41.48 | 40.92 | 0.00 |
FY26 revenue growth was 7.4%, slower than the four-year average of 21.0%, and net profit moved down 2.2%. EPS rose from Rs 37.90 in FY24 to Rs 40.92 in FY26. The FY27 outlook for the Beta Drugs price target depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Beta Drugs converted 10.5% of FY26 revenue into net profit, against 11.5% in FY25, within a five-year range of 10.5% to 13.5%. EBITDA margin was 21.9% in FY26 versus 20.7% in FY25.
In the September 2026 quarter, revenue was Rs 139.24 crore, up 30.9% from the same quarter a year earlier, while net profit of Rs 19.28 crore was up 57.8%. EBITDA came in at Rs 32.03 crore, up 31.8% year on year. The next quarterly result is the first test of whether the earnings assumption behind the Beta Drugs stock target holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.11, and shareholders' equity grew from Rs 92.34 crore in FY22 to Rs 244.77 crore in FY26. Operating cash flow in FY26 was Rs 37.29 crore against capital expenditure of Rs 53.48 crore, leaving negative free cash flow of Rs 16.19 crore. In FY25 free cash flow was negative at Rs 0.72 crore.
Valuation Check for the Beta Drugs Stock Target: PE, Price to Book and ROE
At a PE of 36.78 against an industry PE of 40.13, Beta Drugs trades in line with its industry. Price to book is 4.48 on a book value of Rs 393.57 per share, and return on equity is 11.86%. A PE of 36.78 equals an earnings yield of 2.7%, and the FY26 dividend of Rs 0.00 per share gives a yield of 0.00%.
Shareholding Pattern and Institutional Holding
Promoters held 58.91% of Beta Drugs in September 2026, and promoter holding fell from 64.90% in December 2025 to 58.91% in September 2026. Foreign institutional investors (FII) held 1.37% and domestic institutions (DII) held 6.45%, which puts total institutional holding at 7.82%. FII holding rose from 1.14% in December 2025 to 1.37% in September 2026. Public shareholders own the remaining 33.27%.
Beta Drugs Share Price Targets for the Short Term and 12 Months
Short Term Beta Drugs Stock Target Levels: Technical Setup
At Rs 1,764.20 on 20 November 2026, Beta Drugs trades below its 50-day simple moving average of Rs 1,925.28 and below its 200-day exponential moving average of Rs 1,863.58. The 14-day RSI reads 46.2, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 1,863.58 (200-day exponential moving average) and the nearest support is Rs 990.10 (52-week low). A sustained move above Rs 1,863.58 would improve the short-term setup, while a close below Rs 990.10 would shift attention to the next support.
12 Month Beta Drugs Target Price for 2027
The 12-month target of Rs 1,833 means a move of 3.9% up from Rs 1,764.20 over the next 12 months. It would still leave the stock 34.7% below its 52-week high of Rs 2,807.90. The upside in the base case is thin, so the thesis here leans on the bull case and on patience. Anyone checking the Beta Drugs share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.
How EPS Growth and PE Multiple Change the Beta Drugs Target Price
| EPS Growth | PE 29.42 | PE 36.78 | PE 42.30 |
|---|---|---|---|
| 0.0% (EPS Rs 47.96) | Rs 1,411 | Rs 1,764 | Rs 2,029 |
| 3.9% (EPS Rs 49.83) | Rs 1,466 | Rs 1,833 | Rs 2,108 |
| 9.9% (EPS Rs 52.71) | Rs 1,551 | Rs 1,939 | Rs 2,230 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Beta Drugs price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Beta Drugs Stock Target in 2027
Bull Case Rs 2,230
The bull case Beta Drugs price target needs EPS growth of 9.9%, which lifts forward EPS to Rs 52.71, and a PE multiple that rises 15% to 42.30. That gives Rs 2,230, 26.4% above the current price and below the 52-week high of Rs 2,807.90.
Downside Risk Level Rs 1,411
The downside risk level is not a target. It assumes EPS stays flat at Rs 47.96 and the PE falls 20% to 29.42. That gives Rs 1,411, 20.0% below the current price and above the 52-week low of Rs 990.10.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 9.9% | 42.30 | Rs 2,230 | +26.4% |
| Base Case | 3.9% | 36.78 | Rs 1,833 | +3.9% |
| Downside Risk | 0.0% | 29.42 | Rs 1,411 | -20.0% |
Key Risks to the Beta Drugs Target Price for 2027
Growth Slowdown Risk for the Beta Drugs Price Target
Revenue in the September 2026 quarter was up 30.9% year on year, and FY26 revenue growth was 7.4%. If growth slows from here, the EPS estimate behind the Beta Drugs stock target will need revising.
Liquidity and Size Risk
Beta Drugs has a market capitalisation of Rs 1,962 crore. Institutional holding is 7.82%, and promoters hold 58.91%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.
Valuation and Margin Risk
Net margin was 10.5% in FY26, so a small slip in costs moves profit noticeably. At a PE of 36.78 versus an industry PE of 40.13, a de-rating toward the downside-risk PE of 29.42 would cut the price even if earnings hold.
Market and Technical Risk
Technical indicators add short-term risk: the 14-day RSI is 46.2 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time. Treat every Beta Drugs share price target as a range of outcomes rather than a single point.
What to Watch to Validate the Beta Drugs Target by 2027
The base-case Beta Drugs share price target of Rs 1,833 needs EPS to move from Rs 47.96 to about Rs 49.83, which is 3.9% growth over the next twelve months. The bull case of Rs 2,230 needs 9.9% growth and a higher multiple. Each quarterly result is a checkpoint against those two numbers.
Two figures decide whether the target stays valid: reported quarterly profit against the run rate implied by Rs 49.83 EPS, and the PE of 36.78 against the industry PE. If EPS growth tracks below 3.9%, the base case needs to be lowered; if it runs above, the bull case gains weight.
Check Beta Drugs fundamentals on the Univest Screener
The prices here are as of 20 November 2026, so refresh the Rs 1,764.20 quote before relying on any level. This is a model-based estimate, not investment advice; consult a SEBI-registered advisor before acting on it.
Download the Univest iOS App or Univest Android App to track Beta Drugs live price and get daily stock recommendations.
Conclusion
The Beta Drugs share price target for 2027 is Rs 1,833 in the base case, with Rs 2,230 as the bull case. The support for that view is arithmetic you can check: EPS grew 3.9% a year over FY24 to FY26, and the stock trades at a PE of 36.78. The risks are equally concrete, including a net margin of just 10.5% that leaves profit sensitive to costs and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework for judging the Beta Drugs price target, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Beta Drugs Share Price Target 2027
What is the Beta Drugs share price target for 2027?
Ans. The base-case Beta Drugs share price target for 2027 is Rs 1,833, which is 3.9% above the price of Rs 1,764.20 on 20 November 2026. The bull case is Rs 2,230 and the downside risk level, which is not a target, is Rs 1,411. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.
What is the Beta Drugs share price today?
Ans. As of 20 November 2026, before market open, Beta Drugs (NSE: BETA) is quoted at Rs 1,764.20, which is its last closing price from the previous session. That is 37.2% below the 52-week high of Rs 2,807.90 and 78.2% above the 52-week low of Rs 990.10. The market capitalisation of Rs 1,962 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.
Is Beta Drugs a buy or sell at the current price?
Ans. The data points both ways. On the positive side, EPS has grown 3.9% a year over FY24 to FY26 and the base case implies 3.9% upside; on the cautious side, the net margin is a thin 10.5%, and the downside risk level of Rs 1,411 is 20% below the current price. Whether Beta Drugs fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.
What are the bull case target and downside risk level for Beta Drugs shares?
Ans. The bull case in the Beta Drugs share price target for 2027 is Rs 2,230, which assumes 9.9% EPS growth and a PE of 42.30, a 15% re-rating from today's multiple. That is 26.4% above the current price and below the 52-week high of Rs 2,807.90. The downside risk level is Rs 1,411, which assumes flat EPS and a PE of 29.42, 20% lower than today. It sits 20.0% below the current price and above the 52-week low of Rs 990.10, and it marks a risk to watch, not a target.
What are the main risks to the Beta Drugs price target?
Ans. Four risks matter most for the Beta Drugs share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 1,962 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 29.42 would cut the price even if earnings hold.
What is the PE ratio of Beta Drugs and how does it compare with the industry?
Ans. The PE ratio of Beta Drugs is 36.78, against an industry PE of 40.13, which is a level close to the industry. Price to book is 4.48 and return on equity is 11.86%, and the PE equals an earnings yield of 2.7%. The base case holds the PE unchanged, so the Beta Drugs share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.
Who owns Beta Drugs, and what is the promoter holding?
Ans. Promoters held 58.91% of Beta Drugs in September 2026. FII held 1.37%, DII held 6.45% and the public held 33.27%. Together the two institutional groups hold 7.82%. Shareholding is filed every quarter, so it is worth rechecking after each result.
What were Beta Drugs' latest quarterly results?
Ans. In the September 2026 quarter, Beta Drugs reported revenue of Rs 139.24 crore (up 30.9% year on year) and net profit of Rs 19.28 crore (up 57.8%). For comparison, FY26 full-year revenue growth was 7.4% and net profit moved down 2.2%. Each new quarter either supports or weakens the EPS growth of 3.9% assumed in the base case.
Recent Articles

Baid Finserv Analyst Review 2027: Profit Up 14% on Lower Revenue After a Rights Issue
20 November 2026

BAG Films Analyst Review 2027: News24 Owner's Profit Rises but Sales Slip and Stock Nears Lows
20 November 2026

Avonmore Capital Analyst Review 2027: Profit Up 76% as Consulting Order Book Tops ₹400 Crore
20 November 2026

AVG Logistics Analyst Review 2027: Profit Up 40% After Rights Issue Brings In an 18% Investor
20 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Baid Finserv Analyst Review 2027: Profit Up 14% on Lower Revenue After a Rights Issue
BAG Films Analyst Review 2027: News24 Owner's Profit Rises but Sales Slip and Stock Nears Lows
Avonmore Capital Analyst Review 2027: Profit Up 76% as Consulting Order Book Tops ₹400 Crore
AVG Logistics Analyst Review 2027: Profit Up 40% After Rights Issue Brings In an 18% Investor
Autoline Industries Analyst Review 2027: Sales Up 76% on New Orders, Debt Still High
Popular this week
Ausom Enterprise Analyst Review 2027: ₹849 Crore Sales, ₹3.7 Crore Profit and Razor-Thin Margins

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





